News

The company noted that all patients who complete the APOLLO Phase III trial with patisiran are eligible for enrollmnet in APOLLO-OLE. The trial is designed to assess the

Dex-IN met the primary endpoint of the clinical trial in demonstrating significant pain relief compared with placebo over 48 hours. The Company plans to meet with the FDA

The Phase 1/2 results were previously announced in November 2014. Yotam Nisemblat, BioLineRx Drug Development Director, will present the data in a talk titled BL-7010, a Novel Potential

This patent, entitled "Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria," contains composition claims for the CF-301 sequence and variants having at least 80% identity.

Aquinnah will use the grants to advance the development of lead compounds focusing on the pathophysiology of TDP-43, found in approximately 90% of cases of ALS. ALS is

The goal of the "CRISPR/Cas9 Genome-Wide sgRNA Library Screening Platform" grant is to develop a validated set of reagents that can be used for specific targeted disruption of

Iclaprim is designed to be effective against multi-drug resistant bacteria. The company requested QIDP designation for Iclaprim for two serious and life threatening infections, HABP and acute bacterial

In March this year, the company secured approval from the US Food and Drug Administration (FDA) for Saphris for the acute treatment of manic or mixed episodes associated

Dysport is now approved to treat ULS in adults to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. The company said